Concepedia

Ajay Nirula

AN

Statistics

Publications

42

Citations

6.3K

H-Index

30

Active since

1989

Affiliations

Eli Lilly (United States)(Current)

National Institutes of Health

Harvard University

University of North Carolina at Chapel Hill

Amgen (United States)

Ajay Nirula is an author at Eli Lilly (United States) specializing in life sciences, immunology, and sars-cov-2 infection.

Publications per year

1989–2024

42

Publications

42

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen, Ajay Nirula, Barry N. Heller et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

, , +14

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

Robert Gottlieb, Ajay Nirula, Peter Chen et al. · JAMA · 2021 · 947 citations · Full text

, , +15

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

, , +10

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

Kim Papp, Kristian Reich, C. Paul et al. · British Journal of Dermatology · 2016 · 459 citations

, , +13

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Philip J. Mease, Mark C. Genovese, Maria Greenwald et al. · New England Journal of Medicine · 2014 · 392 citations · Full text

, , +16

1–5 of 42